Reading TECH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TECH free→Reading TECH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TECH free→QuarterlyIQ Insights · TECH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Other Events A copy of the press release issued by Bio-Techne Corporation on May 6, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Officer Transition On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. In addition, the Compan…
Other Events A copy of the press release issued by Bio-Techne Corporation on February 4, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 4, 2026, describing the results of operations for the quarter and six months ended December 31, 2025, and its financial condition as of December 31, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Other Events A copy of the press release issued by Bio-Techne Corporation on November 5, 2025, announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation (the “Company”) on November 5, 2025, describing the results of operations for the quarter ended September 30, 2025 and its financial condition as of September 30, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Other Events A copy of the press release issued by Bio-Techne Corporation on August 6, 2025 announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on August 6, 2025, describing the results of operations for the quarter and year ended June 30, 2025, and its financial condition as of June 30, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Other Events A copy of the press release issued by Bio-Techne Corporation on May 7, 2025 announcing a cash dividend and share repurchase program is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on May 7, 2025, describing the results of operations for the quarter ended March 31, 2025, and its financial condition as of March 31, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise sub…
Regulation FD Disclosure. On April 30, 2025, the Board of Directors of Bio-Techne Corporation (the “ Company ”) authorized a share repurchase program (the “ Share Repurchase Program ”), pursuant to which the Company may, from time to time, purchase shares of its common stock for an aggregate repurchase not to exceed a total of $500,000,000. This replaces the Company’s previous stock repurchase authorization approved by the Board on February 2, 2022. There is no time limit on the Share Repurch…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Quarterly Report of Bio-Techne Corporation (the “Company”) for the quarter ended September 30, 2024 and filed with the U.S. Securities and Exchange Commission on November 5, 2024, the expiration dates with respect to 794,400 shares subject to outstanding vested options held by former employees was under dispute. In 20…
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 5, 2025, describing the results of operations for the quarter ended December 31, 2024, and its financial condition as of December 31, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or ot…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director. Dr. Herr’s tenure as a director will begin on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Amy E. Herr, Ph.D., is currently a Chancellor’s Pr…
Other Events A copy of the press release issued by Bio-Techne Corporation on February 5, 2025 announcing a cash dividend is attached hereto as Exhibit 99.2. A copy of the press release issued by Bio-Techne Corporation on February 4, 2025, announcing Dr. Herr’s appointment is attached hereto as Exhibit 99.3.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 30, 2024, the Compensation Committee of the Board of Directors of Bio-Techne Corporation (the “Company”) granted James Hippel, the Company’s Executive Vice President, Chief Financial Officer, a one-time restricted stock unit award in the amount of 34,634 shares pursuant to the Company’s 2020 Equity Incentive Plan, as amended to date (the…
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation (the “Company”) on October 30, 2024, describing the results of operations for the quarter ended September 30, 2024 and its financial condition as of September 30, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Other Events A copy of the press release issued by Bio-Techne Corporation on October 30, 2024, announcing a cash dividend is attached hereto as Exhibit 99.2.
Other Events A copy of the press release issued by Bio-Techne Corporation on August 7, 2024 announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on August 7, 2024, describing the results of operations for the quarter and year ended June 30, 2024, and its financial condition as of June 30, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth…
Other Events A copy of the press release issued by Bio-Techne Corporation on May 1, 2024 announcing a cash dividend is attached hereto as Exhibit 99.2.
Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on May 1, 2024, describing the results of operations for the quarter ended March 31, 2024, and its financial condition as of March 31, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise sub…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director. Judith Klimovsky, M.D., is currently the Executive Vice President and Chief Development Officer at Genmab A/S,…
Other Events A copy of the press release issued by Bio-Techne Corporation on February 1, 2024 announcing a cash dividend is attached hereto as Exhibit 99.2.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.